PTH-067 High quality colon cleansing with novel 1l peg-based bowel preparation ner1006 versus current alternatives

Abstract

Results DEMOGRAPHY: 528 subjects were colonoscoped at one single centre. The aspirin group (n=112) had 74 (66%) males and a median age of 68 years. The NSAID group (n=46) had 23 (50%) males and a median age of 58 years. The control group, not using either of these agents (n=370), had 207 (56%) males and a median age of 63 years (p<0.001 vs aspirin users; p=0.012 vs NSAID users). POL-YPS: ASPIRIN vs CONTROLS. Polyps>5 mm were found in 21 (19%) subjects taking aspirin vs 99 (27%) controls [odds ratio, OR, 0.57; 95% confidence intervals, CI, (0.33-0.98); p=0.042]. Polyps >5 mm or cancer were found in 24 (21%) aspirin users vs 118 (32%) controls [OR, 0.50; 95% CI (0.30.0.84); p=0.009]. POLYPS: NSAIDs vs CONTROLS. Polyps >5 mm were found in 5 (11%) subjects taking NSAIDs vs 99 (27%) controls [OR, 0.36; 95% CI (0.14-0.86); p=0.036]. Polyps >5 mm or cancer were found in 6 (13%) NSAID users vs 118 (32%) controls [OR, 0.35; 95% CI (0.14-0.86); p=0.022]. Conclusions (1) In this bowel cancer screening program, subjects taking low-dose aspirin were older while those taking NSAIDs were younger than controls not using either of these agents. (2) After adjusting the odds ratios for age and sex, the use of aspirin or NSAIDs was associated with lower prevalence of dysplastic colonic polyps or cancers.These results provide further evidence for the potential use of aspirin or NSAIDs for bowel cancer chemoprevention.